Refractory Multiple Myeloma clinical trials in Georgia

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

Test of an MMSET inhibitor for relapsed multiple myeloma

This Phase 1 trial tests a new drug that targets MMSET in people whose multiple myeloma has returned or not responded to prior treatment. It aims to find a safe dose and see whether it can shrink myeloma in this setting.

Comparing a new CAR-T therapy to standard treatments for multiple myeloma

This trial tests a new dual-targeted cell therapy (AZD0120) against standard regimens for people with multiple myeloma that has come back or not responded to treatment. It aims to see if the new therapy works better than standard options.

Comparing new treatments for relapsed multiple myeloma

This trial tests if a new medicine called linvoseltamab, alone or combined with carfilzomib, works better than the usual treatments for people with multiple myeloma that has come back or stopped responding after 1 to 3 prior therapies.

Study of Inobrodib, Pomalidomide, and Dexamethasone for Multiple Myeloma

This trial tests a new combination of three drugs—inobrodib, pomalidomide, and dexamethasone—for people with multiple myeloma that has come back or stopped responding to treatment. The goal is to see if this new drug adds benefit for patients who have tried other therapies.

Comparing a new drug to Teclistamab for advanced multiple myeloma

This study tests a new experimental drug (JNJ-79635322) compared to another targeted immunotherapy (Teclistamab) for people with multiple myeloma that has returned or not responded after several prior treatments.

Comparing Two New Myeloma Treatments: JNJ-79635322 vs Teclistamab

This study compares two new antibody-based drugs (JNJ-79635322 and teclistamab) to see which works better for multiple myeloma that has come back or stopped responding to prior treatment. Both drugs are designed to help your immune system fight myeloma cells.

Study of a new drug for relapsed or refractory multiple myeloma

This trial tests an experimental drug called JNJ-79635322 for people with multiple myeloma that has come back or hasn't responded to at least three previous treatments, including a PI, an IMiD, and a CD38-targeted antibody. The goal is to see if this new drug can help control the disease.

Study of a new drug combination for multiple myeloma

This trial tests a new drug (JNJ-79635322) combined with other treatments like daratumumab or pomalidomide for people with multiple myeloma. It aims to see if these combinations are safe and effective for newly diagnosed or previously treated patients.

Belantamab mafodotin combinations for relapsed multiple myeloma

This trial tests a new drug called belantamab mafodotin (a targeted antibody therapy) combined with standard treatments for multiple myeloma that has come back or stopped responding. It looks at three different drug combinations to see which works best for people who have had 1 or 2 prior treatments.

New treatment vs standard care for relapsed multiple myeloma

This trial tests a new treatment called BMS-986393 (a type of CAR T-cell therapy) compared to standard treatments for adults with multiple myeloma that has come back or is not responding to therapy, and who have already been treated with lenalidomide (Revlimid). The goal is to see if the new treatment works better.

Safety study of HDP-101 for relapsed myeloma patients

This early-phase trial tests whether HDP-101 is safe and can potentially help adults with multiple myeloma that has come back or didn’t respond to standard treatments. It focuses on people who have already tried key myeloma medicines and still have measurable disease.

Study of CAR-T cell therapy in combinations for multiple myeloma

This trial tests a new CAR-T cell therapy (called arlocabtagene autoleucel) combined with other drugs for multiple myeloma that has returned or stopped responding. It aims to find a safe and effective dose while tracking how well the treatment works.

Study of linvoseltamab for hard-to-treat multiple myeloma

This trial tests linvoseltamab, an experimental antibody medicine, in adults whose multiple myeloma has come back or does not respond to treatment. It may help some people by targeting myeloma cells after multiple prior therapies have failed.

AZD0305 alone or with other drugs for multiple myeloma

This trial tests a new drug called AZD0305, either by itself or combined with other cancer drugs, for people with multiple myeloma. It aims to see if the treatment is safe and effective.

Test mezigdomide vs pomalidomide with standard drugs for myeloma

This Phase 3 study compares two combination treatments for multiple myeloma that has come back or not gone away (relapsed or refractory). It aims to see whether mezigdomide, along with bortezomib and dexamethasone, works better than pomalidomide with those same medicines.

Vitamin D3 supplement for people with multiple myeloma

This early-phase study tests whether taking a Vitamin D3 supplement can be safe and helpful for people with symptomatic multiple myeloma. It may help researchers understand how Vitamin D affects the disease and how patients tolerate treatment.

IDP-023 alone or with other antibodies for blood cancers

This trial tests an experimental drug, IDP-023, given alone or with antibody therapies for people with advanced blood cancers like multiple myeloma or non-Hodgkin lymphoma that have not responded to previous treatments. The goal is to see if it can shrink tumors or slow the disease.

Etentamig vs standard therapy for relapsed myeloma

This trial tests a new IV treatment called etentamig compared to standard therapies for people with multiple myeloma that has come back or stopped responding. It may be an option if you've already tried at least two different treatments, including common drug classes.

Combination therapy for relapsed or refractory multiple myeloma

This trial tests a new combination of two drugs, elranatamab and iberdomide, for people whose multiple myeloma has returned or stopped responding to previous treatments. The goal is to see if this combination can help control the disease.

CAR T cell therapy for multiple myeloma

This trial tests a new CAR T cell therapy (arlocabtagene autoleucel) that targets a protein called GPRC5D on myeloma cells. It is for people whose multiple myeloma has come back or is not responding after trying at least four different types of treatment.

Testing an experimental drug OPN-6602 for advanced multiple myeloma

This trial tests an experimental oral drug called OPN-6602 for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The main goal is to see if the drug is safe and tolerable, and to find the best dose.

Gene therapy study for hard-to-treat multiple myeloma

This study tests a new gene therapy for people with multiple myeloma that has come back or stopped responding to at least 3 prior treatments. The therapy is designed to help your immune system fight the cancer cells more effectively.

mRNA vaccine for relapsed or refractory multiple myeloma

This trial tests an experimental mRNA therapy called mRNA-2808 for people with multiple myeloma that has returned or stopped responding to prior treatments. It aims to see if it can help control the disease.